173 related articles for article (PubMed ID: 36643868)
21. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.
Browne TJ; Hirsch MS; Brodsky G; Welch WR; Loda MF; Rubin MA
Hum Pathol; 2004 Dec; 35(12):1462-8. PubMed ID: 15619204
[TBL] [Abstract][Full Text] [Related]
22. TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer.
Yamoah K; Lal P; Awasthi S; Naghavi AO; Rounbehler RJ; Gerke T; Berglund AE; Pow-Sang JM; Schaeffer EM; Dhillon J; Park JY; Rebbeck TR
Prostate; 2021 Feb; 81(2):109-117. PubMed ID: 33141952
[TBL] [Abstract][Full Text] [Related]
23. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes.
Gu Y; Kim KH; Ko D; Nakamura K; Yasunaga Y; Moul JW; Srivastava S; Arnstein P; Rhim JS
Int J Oncol; 2004 Oct; 25(4):1057-64. PubMed ID: 15375556
[TBL] [Abstract][Full Text] [Related]
24. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer.
Zhou M; Jiang Z; Epstein JI
Am J Surg Pathol; 2003 Jun; 27(6):772-8. PubMed ID: 12766580
[TBL] [Abstract][Full Text] [Related]
25. Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.
Huang YH; Zhang YQ; Huang JT
Asian J Androl; 2019; 21(3):291-295. PubMed ID: 30924452
[TBL] [Abstract][Full Text] [Related]
26. Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.
Hakozaki Y; Murata T; Yokoyama M; Matsushima H; Ogawa M; Masuda T; Hirai Y; Kume H
Urol Case Rep; 2018 Sep; 20():67-69. PubMed ID: 30009133
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger I; Fotakis G; Offermann A; Goveia J; Daum S; Salcher S; Noureen A; Timmer-Bosscha H; Schäfer G; Walenkamp A; Perner S; Beatovic A; Moisse M; Plattner C; Krogsdam A; Haybaeck J; Sopper S; Thaler S; Keller MA; Klocker H; Trajanoski Z; Wolf D; Pircher A
Mol Cancer; 2022 Jun; 21(1):132. PubMed ID: 35717322
[TBL] [Abstract][Full Text] [Related]
28. The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostate.
Tien JC; Liao L; Liu Y; Liu Z; Lee DK; Wang F; Xu J
Int J Biol Sci; 2014; 10(10):1116-27. PubMed ID: 25332686
[TBL] [Abstract][Full Text] [Related]
29. A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants.
Jiang N; Zhu S; Chen J; Niu Y; Zhou L
PLoS One; 2013; 8(10):e74386. PubMed ID: 24130666
[TBL] [Abstract][Full Text] [Related]
30. Glyoxalase 2 drives tumorigenesis in human prostate cells in a mechanism involving androgen receptor and p53-p21 axis.
Antognelli C; Ferri I; Bellezza G; Siccu P; Love HD; Talesa VN; Sidoni A
Mol Carcinog; 2017 Sep; 56(9):2112-2126. PubMed ID: 28470764
[TBL] [Abstract][Full Text] [Related]
31. α-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues.
Ouyang B; Leung YK; Wang V; Chung E; Levin L; Bracken B; Cheng L; Ho SM
Urology; 2011 Jan; 77(1):249.e1-7. PubMed ID: 21195844
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-99b-5p targets mTOR/AR axis, induces autophagy and inhibits prostate cancer cell proliferation.
Niture S; Tricoli L; Qi Q; Gadi S; Hayes K; Kumar D
Tumour Biol; 2022; 44(1):107-127. PubMed ID: 35811549
[TBL] [Abstract][Full Text] [Related]
33. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
34. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.
Warrick JI; Humphrey PA
Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.
Gumulec J; Masarik M; Krizkova S; Hlavna M; Babula P; Hrabec R; Rovny A; Masarikova M; Sochor J; Adam V; Eckschlager T; Kizek R
Neoplasma; 2012; 59(2):191-201. PubMed ID: 22248277
[TBL] [Abstract][Full Text] [Related]
36. A novel human cancer culture model for the study of prostate cancer.
Yasunaga Y; Nakamura K; Ko D; Srivastava S; Moul JW; Sesterhenn IA; McLeod DG; Rhim JS
Oncogene; 2001 Nov; 20(55):8036-41. PubMed ID: 11753687
[TBL] [Abstract][Full Text] [Related]
37. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
Kumar-Sinha C; Shah RB; Laxman B; Tomlins SA; Harwood J; Schmitz W; Conzelmann E; Sanda MG; Wei JT; Rubin MA; Chinnaiyan AM
Am J Pathol; 2004 Mar; 164(3):787-93. PubMed ID: 14982833
[TBL] [Abstract][Full Text] [Related]
38. Prostate Cancer Diagnosis Using Urine Sediment Analysis-Based α-Methylacyl-CoA Racemase Score: A Single-Center Experience.
Ji J; Chen X; Xu Y; Cao Z; Xu H; Kong C; Wang F; Sun Y
Cancer Control; 2019; 26(1):1073274819887697. PubMed ID: 31793344
[TBL] [Abstract][Full Text] [Related]
39. Race-associated expression of MHC class I polypeptide-related sequence A (MICA) in prostate cancer.
Sakiyama MJ; Espinoza I; Reddy A; de Carlo F; Kumar A; Levenson AS; Bae S; Zhou X; Claudio PP; Lewin J; Manucha V; Pound CR; Vijayakumar S; Gomez CR
Exp Mol Pathol; 2019 Jun; 108():173-182. PubMed ID: 31004600
[TBL] [Abstract][Full Text] [Related]
40. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
